{
  "created_at": "2021-04-04T21:53:25.730Z",
  "title": "New HIV vaccine with a 97% antibody response rate in phase I human trials",
  "url": "https://www.europeanpharmaceuticalreview.com/news/141892/novel-hiv-vaccine-approach-shows-promise-in-landmark-first-in-human-trial/",
  "author": "MKais",
  "points": 663,
  "num_comments": 29,
  "_tags": [
    "story",
    "author_MKais",
    "story_26690751",
    "front_page"
  ],
  "objectID": "26690751",
  "original_created_at": "2021-04-04T16:23:57.000Z",
  "localize": [
    {
      "locale": "zh",
      "title": "新型HIV疫苗I期人体试验抗体应答率达97%。"
    },
    {
      "locale": "zh-Hant",
      "title": "新型HIV疫苗I期人體試驗抗體應答率達97%。"
    },
    {
      "locale": "ja-JA",
      "title": "抗体反応率97%の新規HIVワクチンをヒトでの第I相試験に投入"
    },
    {
      "locale": "ja",
      "title": "抗体反応率97%の新規HIVワクチンをヒトでの第I相試験に投入"
    }
  ],
  "source_updated_at": 1617961885333,
  "image": "https://www.europeanpharmaceuticalreview.com/wp-content/uploads/HIV-Vaccine-1-scaled-e1612534046138.jpg"
}